Top

Annals of Hematology

Published in:

01-08-2017 | Letter to the Editor

Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

Authors: Chen Tian, Hongliang Yang, Lei Zhu, Qing Zhang, Zeng Cao, Yizhuo Zhang

Published in: Annals of Hematology | Issue 8/2017

Excerpt

Dear Editor, …

Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P (2017) Marizomib for central nervous system-multiple myeloma. Br J Haematol 177(2):221–225CrossRefPubMed

Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D (2017) Current strategies for the immunotherapy of multiple myeloma. Oncology (Williston Park) 31(1):55–63

Singh N (2016) Recent advances in engineered T cell therapies targeting B cell malignancies. Discov Med 22(121):215–220PubMed

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions ofmultiple myeloma. Blood 128(13):1688–1700CrossRefPubMed

Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T (2016) Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br J Haematol 172(5):685–698CrossRefPubMed

Geyer MB, Brentjens RJ (2016) Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy 18(11):1393–1409CrossRefPubMed

Title: Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement
Authors: Chen Tian
Hongliang Yang
Lei Zhu
Qing Zhang
Zeng Cao
Yizhuo Zhang
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3029-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2017

Vitamin D and plasma cell dyscrasias: reviewing the significance

Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution

Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden

Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience

Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page